Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids
- PMID: 8993938
- DOI: 10.1097/00019501-199611000-00004
Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids
Abstract
Background: Plasminogen activator inhibitor type-1 (PAI-1) implicated as a determinant of thrombosis, and possibly of atherosclerosis, is increased approximately four-fold in the blood of subjects with type II diabetes, and the increase is closely correlated with concentrations of insulin. Insulin can stimulate expression of PAI-1 in vitro, but infusions of insulin in human subjects have not increased PAI-1 in blood in acute, euglycemic clamp studies.
Objective: To determine whether the dichotomy reflects interactions between insulin and both very-low-density lipoprotein (VLDL)-bound triglycerides (VLDL-TG) and albumin-bound nonesterified (free) fatty acids (FFA) affecting PAI-1 elaboration.
Methods: HepG2 cells (human hepatoma cell line) were exposed to insulin, VLDL, and FFA alone and in selected combinations for 24 h.
Results: Striking synergistic effects were observed. Thus, compared with control, pathophysiologic concentrations of insulin increased PAI-1 accumulation in conditioned media modestly, as did VLDL, but the combination elicited a marked nine-fold increase (control PAI-130 +/- 2 ng/ml, PAI-1 with 400 mg/dl VLDL-TG 97 +/- 6 ng/ml; with 4 nmol/1 insulin 45 +/- 6 ng/ml, with 400 mg/dl VLDL-TG plus 4 nmol/1 insulin 276 +/- 47 ng/ml; P < 0.01 for the combination compared with control or with either agent alone). Similarly, a modest increase was found either with insulin or with FFA alone, but a synergistic increase was evident when they were combined (control 27 +/- 3 ng/ml; 1 mmol/l FFA 36 +/- 2 ng/ml; 10 nmol/l insulin 59 +/- 6 ng/ml; 1 mmol/l FFA plus 10 nmol/l insulin 82 +/- 1 ng/ml; P < 0.01 for the combination compared with control or with either agent alone).
Conclusion: The combination of increased insulin with elevated VLDL-TG and increased FFA appears to cause the increase in PAI-1 in blood of subjects with type II diabetes mellitus and other insulin-resistant states, providing novel and promising targets for normalizing altered fibrinolytic system potential and thereby ameliorating the associated predisposition to persistent thrombosis and possibly atherosclerosis.
Similar articles
-
Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia.Exp Clin Endocrinol Diabetes. 2003 Aug;111(5):246-50. doi: 10.1055/s-2003-41284. Exp Clin Endocrinol Diabetes. 2003. PMID: 12951628 Review.
-
Effect of fatty acid chain length and thioesterification on the augmentation of expression of plasminogen activator inhibitor-1.Nutr Metab Cardiovasc Dis. 2002 Dec;12(6):325-30. Nutr Metab Cardiovasc Dis. 2002. PMID: 12669679
-
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.Diabetes. 2000 Apr;49(4):633-9. doi: 10.2337/diabetes.49.4.633. Diabetes. 2000. PMID: 10871202
-
Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state.Diabetes Care. 1996 Apr;19(4):390-3. doi: 10.2337/diacare.19.4.390. Diabetes Care. 1996. PMID: 8729170 Review.
-
Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL.Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):89-96. doi: 10.1161/01.atv.16.1.89. Arterioscler Thromb Vasc Biol. 1996. PMID: 8548432
Cited by
-
PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target.Int J Mol Sci. 2021 Mar 20;22(6):3170. doi: 10.3390/ijms22063170. Int J Mol Sci. 2021. PMID: 33804680 Free PMC article. Review.
-
A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?Int J Mol Sci. 2021 Mar 8;22(5):2721. doi: 10.3390/ijms22052721. Int J Mol Sci. 2021. PMID: 33800359 Free PMC article. Review.
-
The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance.Scientifica (Cairo). 2012;2012:525374. doi: 10.6064/2012/525374. Epub 2012 Aug 30. Scientifica (Cairo). 2012. PMID: 24278711 Free PMC article. Review.
-
PAI-1 and diabetes: a journey from the bench to the bedside.Diabetes Care. 2012 Oct;35(10):1961-7. doi: 10.2337/dc12-0638. Diabetes Care. 2012. PMID: 22996180 Free PMC article. No abstract available.
-
Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome.Hypertension. 2012 Apr;59(4):893-8. doi: 10.1161/HYPERTENSIONAHA.111.189589. Epub 2012 Feb 21. Hypertension. 2012. PMID: 22353614 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous